PARSIPPANY, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism. The first regards the use of Tirosint-SOL in the presence of proton pump inhibitor (PPI) therapy. The second regards the timing of Tirosint-SOL administration. Both label changes help to differentiate Tirosint-SOL from other levothyroxine therapies.
Enforcement Report - Week of November 15, 2023
Zydus Lifesciences gets USFDA nod to market generic drug
Enforcement Report - Week of March 8, 2023
Enforcement Report - Week of March 1, 2023
FDA Confirms Paragraph IV Patent Litigation for Levothyroxine Sodium Oral Solution
Enforcement Report - Week of February 22, 2023
IBSA Pharma Inc. Issues Voluntary Nationwide Recall of Select Lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution Due to Subpotency
Ascent's Generic Levothyroxine Sodium Receives Approval in the U.S.
Macleods' Generic Levothyroxine Sodium Receives Approval in the U.S.